Investors
FAQs
What does Niki BioSolutions do?
Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs and providing high-quality genomic and biomarker testing solutions through its CLIA-certified, CAP-accredited laboratory. The company supports precision medicine across therapeutic areas that include neurodegeneration and other brain health conditions and collaborates with academic centers, disease foundations, and biopharma companies.
How are Niki BioSolutions, Aptorum Group, and DiamiR Biosciences related?
Niki BioSolutions was formed through the business combination of Aptorum Group and DiamiR Biosciences, completed on July 20, 2026. In connection with the transaction, Aptorum became a Delaware corporation and changed its name to Niki BioSolutions, Inc. DiamiR became a wholly owned subsidiary of the company.
Where does Niki BioSolutions stock trade, and what is its ticker symbol?
Niki BioSolutions common stock trades on the Nasdaq Capital Market under the ticker symbol NIKI.
When did the company begin trading as Niki BioSolutions?
The company began trading under the Niki BioSolutions name and NIKI ticker symbol on July 20, 2026. It previously traded as Aptorum Group under the symbol APM.
When does Niki BioSolutions’ fiscal year end?
The company’s fiscal year ends on December 31.
Does Niki BioSolutions pay a dividend?
Niki BioSolutions does not currently pay cash dividends and does not anticipate paying cash dividends in the foreseeable future. Any future dividend decision would be at the discretion of the Board of Directors.
Who is Niki BioSolutions’ transfer agent?
The company’s transfer agent is Continental Stock Transfer & Trust Company.
Whom should I contact about my shareholder account?
If your shares are registered directly in your name, contact Continental Stock Transfer & Trust Company for assistance with address changes, stock transfers, or lost certificates.
If your shares are held through a brokerage account, contact your broker for assistance.
How can I receive company updates?
Subscribe through the Email Alerts page to receive the company updates available through the subscription service.
Who should I contact with investor relations questions?
Ben Shamsian
Lytham Partners
shamsian@lythampartners.com